Table 2. Response Outcome After Repeated cTACE During Follow-Up.
| Response | Indication to Repeated cTACE | ||||
|---|---|---|---|---|---|
| Recurrence After CR, No. (%) | Non-CR | ||||
| PR | SD | PD | Patients Experiencing Outcome, % | ||
| Tumor response to second cTACE | |||||
| CR | 86 (57.3) | 76 | 14 | 83 | 11.0 |
| PR | 25 (16.7) | 78 | 110 | 112 | 19.0 |
| SD | 10 (6.7) | 5 | 660 | 201 | 54.8 |
| PD | 29 (19.3) | 2 | 59 | 179 | 15.2 |
| Tumor response to third cTACE | |||||
| CR | 61 (48.8) | 55 | 6 | 29 | 13.3 |
| PR | 53 (42.4) | 43 | 61 | 17 | 17.9 |
| SD | 1 (0.8) | 1 | 379 | 2 | 56.6 |
| PD | 10 (8) | 1 | 57 | 24 | 12.2 |
| Tumor response to fourth cTACE | |||||
| CR | 21 (39.6) | 32 | 7 | 12 | 17.3 |
| PR | 24 (45.3) | 38 | 48 | 5 | 30.8 |
| SD | 2 (3.8) | 2 | 120 | 1 | 41.7 |
| PD | 6 (11.3) | 1 | 20 | 9 | 10.2 |
Abbreviations: CR, complete response; cTACE, conventional transarterial chemoembolization; PD, progressive disease; PR, partial response; SD, stable disease.